we are going to see a correction on this stock. They don't keep going up forever.
The correction will be a massive up tick in my opinion. They have a fierce pipeline with several potential blockbuster drugs in phase 3.
their earnings report clearly shows that they are making money from tysabri. that is the reason they are overpaid for it. their p/e of 29 is joke.i think the next bubble is pharma/biotech.
Sentiment: Strong Sell